Program Snapshot

The Common Fund’s Regulatory Science program is a collaborative effort to accelerate the development and use of new tools, standards and approaches to efficiently develop medical products and to more effectively evaluate medical product safety, efficacy and quality. The current phase of the program focuses on the development of cutting edge microphysiological systems (MPS), or “tissue chips”, to more accurately predict drug safety and efficacy in humans.

This page last reviewed on June 21, 2017